Cargando…
MECP2 Mutation Interrupts Nucleolin–mTOR–P70S6K Signaling in Rett Syndrome Patients
Rett syndrome (RTT) is a severe and rare neurological disorder that is caused by mutations in the X-linked MECP2 (methyl CpG-binding protein 2) gene. MeCP2 protein is an important epigenetic factor in the brain and in neurons. In Mecp2-deficient neurons, nucleoli structures are compromised. Nucleoli...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305968/ https://www.ncbi.nlm.nih.gov/pubmed/30619462 http://dx.doi.org/10.3389/fgene.2018.00635 |
_version_ | 1783382687141068800 |
---|---|
author | Olson, Carl O. Pejhan, Shervin Kroft, Daniel Sheikholeslami, Kimia Fuss, David Buist, Marjorie Ali Sher, Annan Del Bigio, Marc R. Sztainberg, Yehezkel Siu, Victoria Mok Ang, Lee Cyn Sabourin-Felix, Marianne Moss, Tom Rastegar, Mojgan |
author_facet | Olson, Carl O. Pejhan, Shervin Kroft, Daniel Sheikholeslami, Kimia Fuss, David Buist, Marjorie Ali Sher, Annan Del Bigio, Marc R. Sztainberg, Yehezkel Siu, Victoria Mok Ang, Lee Cyn Sabourin-Felix, Marianne Moss, Tom Rastegar, Mojgan |
author_sort | Olson, Carl O. |
collection | PubMed |
description | Rett syndrome (RTT) is a severe and rare neurological disorder that is caused by mutations in the X-linked MECP2 (methyl CpG-binding protein 2) gene. MeCP2 protein is an important epigenetic factor in the brain and in neurons. In Mecp2-deficient neurons, nucleoli structures are compromised. Nucleoli are sites of active ribosomal RNA (rRNA) transcription and maturation, a process mainly controlled by nucleolin and mechanistic target of rapamycin (mTOR)–P70S6K signaling. Currently, it is unclear how nucleolin–rRNA–mTOR–P70S6K signaling from RTT cellular model systems translates into human RTT brain. Here, we studied the components of nucleolin–rRNA–mTOR–P70S6K signaling in the brain of RTT patients with common T158M and R255X mutations. Immunohistochemical examination of T158M brain showed disturbed nucleolin subcellular localization, which was absent in Mecp2-deficient homozygous male or heterozygote female mice, compared to wild type (WT). We confirmed by Western blot analysis that nucleolin protein levels are altered in RTT brain, but not in Mecp2-deficient mice. Further, we studied the expression of rRNA transcripts in Mecp2-deficient mice and RTT patients, as downstream molecules that are controlled by nucleolin. By data mining of published ChIP-seq studies, we showed MeCP2-binding at the multi-copy rRNA genes in the mouse brain, suggesting that rRNA might be a direct MeCP2 target gene. Additionally, we observed compromised mTOR–P70S6K signaling in the human RTT brain, a molecular pathway that is upstream of rRNA–nucleolin molecular conduits. RTT patients showed significantly higher phosphorylation of active mTORC1 or mTORC2 complexes compared to age- and sex-matched controls. Correlational analysis of mTORC1/2–P70S6K signaling pathway identified multiple points of deviation from the control tissues that may result in abnormal ribosome biogenesis in RTT brain. To our knowledge, this is the first report of deregulated nucleolin–rRNA–mTOR–P70S6K signaling in the human RTT brain. Our results provide important insight toward understanding the molecular properties of human RTT brain. |
format | Online Article Text |
id | pubmed-6305968 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63059682019-01-07 MECP2 Mutation Interrupts Nucleolin–mTOR–P70S6K Signaling in Rett Syndrome Patients Olson, Carl O. Pejhan, Shervin Kroft, Daniel Sheikholeslami, Kimia Fuss, David Buist, Marjorie Ali Sher, Annan Del Bigio, Marc R. Sztainberg, Yehezkel Siu, Victoria Mok Ang, Lee Cyn Sabourin-Felix, Marianne Moss, Tom Rastegar, Mojgan Front Genet Genetics Rett syndrome (RTT) is a severe and rare neurological disorder that is caused by mutations in the X-linked MECP2 (methyl CpG-binding protein 2) gene. MeCP2 protein is an important epigenetic factor in the brain and in neurons. In Mecp2-deficient neurons, nucleoli structures are compromised. Nucleoli are sites of active ribosomal RNA (rRNA) transcription and maturation, a process mainly controlled by nucleolin and mechanistic target of rapamycin (mTOR)–P70S6K signaling. Currently, it is unclear how nucleolin–rRNA–mTOR–P70S6K signaling from RTT cellular model systems translates into human RTT brain. Here, we studied the components of nucleolin–rRNA–mTOR–P70S6K signaling in the brain of RTT patients with common T158M and R255X mutations. Immunohistochemical examination of T158M brain showed disturbed nucleolin subcellular localization, which was absent in Mecp2-deficient homozygous male or heterozygote female mice, compared to wild type (WT). We confirmed by Western blot analysis that nucleolin protein levels are altered in RTT brain, but not in Mecp2-deficient mice. Further, we studied the expression of rRNA transcripts in Mecp2-deficient mice and RTT patients, as downstream molecules that are controlled by nucleolin. By data mining of published ChIP-seq studies, we showed MeCP2-binding at the multi-copy rRNA genes in the mouse brain, suggesting that rRNA might be a direct MeCP2 target gene. Additionally, we observed compromised mTOR–P70S6K signaling in the human RTT brain, a molecular pathway that is upstream of rRNA–nucleolin molecular conduits. RTT patients showed significantly higher phosphorylation of active mTORC1 or mTORC2 complexes compared to age- and sex-matched controls. Correlational analysis of mTORC1/2–P70S6K signaling pathway identified multiple points of deviation from the control tissues that may result in abnormal ribosome biogenesis in RTT brain. To our knowledge, this is the first report of deregulated nucleolin–rRNA–mTOR–P70S6K signaling in the human RTT brain. Our results provide important insight toward understanding the molecular properties of human RTT brain. Frontiers Media S.A. 2018-12-19 /pmc/articles/PMC6305968/ /pubmed/30619462 http://dx.doi.org/10.3389/fgene.2018.00635 Text en Copyright © 2018 Olson, Pejhan, Kroft, Sheikholeslami, Fuss, Buist, Ali Sher, Del Bigio, Sztainberg, Siu, Ang, Sabourin-Felix, Moss and Rastegar. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Olson, Carl O. Pejhan, Shervin Kroft, Daniel Sheikholeslami, Kimia Fuss, David Buist, Marjorie Ali Sher, Annan Del Bigio, Marc R. Sztainberg, Yehezkel Siu, Victoria Mok Ang, Lee Cyn Sabourin-Felix, Marianne Moss, Tom Rastegar, Mojgan MECP2 Mutation Interrupts Nucleolin–mTOR–P70S6K Signaling in Rett Syndrome Patients |
title | MECP2 Mutation Interrupts Nucleolin–mTOR–P70S6K Signaling in Rett Syndrome Patients |
title_full | MECP2 Mutation Interrupts Nucleolin–mTOR–P70S6K Signaling in Rett Syndrome Patients |
title_fullStr | MECP2 Mutation Interrupts Nucleolin–mTOR–P70S6K Signaling in Rett Syndrome Patients |
title_full_unstemmed | MECP2 Mutation Interrupts Nucleolin–mTOR–P70S6K Signaling in Rett Syndrome Patients |
title_short | MECP2 Mutation Interrupts Nucleolin–mTOR–P70S6K Signaling in Rett Syndrome Patients |
title_sort | mecp2 mutation interrupts nucleolin–mtor–p70s6k signaling in rett syndrome patients |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305968/ https://www.ncbi.nlm.nih.gov/pubmed/30619462 http://dx.doi.org/10.3389/fgene.2018.00635 |
work_keys_str_mv | AT olsoncarlo mecp2mutationinterruptsnucleolinmtorp70s6ksignalinginrettsyndromepatients AT pejhanshervin mecp2mutationinterruptsnucleolinmtorp70s6ksignalinginrettsyndromepatients AT kroftdaniel mecp2mutationinterruptsnucleolinmtorp70s6ksignalinginrettsyndromepatients AT sheikholeslamikimia mecp2mutationinterruptsnucleolinmtorp70s6ksignalinginrettsyndromepatients AT fussdavid mecp2mutationinterruptsnucleolinmtorp70s6ksignalinginrettsyndromepatients AT buistmarjorie mecp2mutationinterruptsnucleolinmtorp70s6ksignalinginrettsyndromepatients AT alisherannan mecp2mutationinterruptsnucleolinmtorp70s6ksignalinginrettsyndromepatients AT delbigiomarcr mecp2mutationinterruptsnucleolinmtorp70s6ksignalinginrettsyndromepatients AT sztainbergyehezkel mecp2mutationinterruptsnucleolinmtorp70s6ksignalinginrettsyndromepatients AT siuvictoriamok mecp2mutationinterruptsnucleolinmtorp70s6ksignalinginrettsyndromepatients AT angleecyn mecp2mutationinterruptsnucleolinmtorp70s6ksignalinginrettsyndromepatients AT sabourinfelixmarianne mecp2mutationinterruptsnucleolinmtorp70s6ksignalinginrettsyndromepatients AT mosstom mecp2mutationinterruptsnucleolinmtorp70s6ksignalinginrettsyndromepatients AT rastegarmojgan mecp2mutationinterruptsnucleolinmtorp70s6ksignalinginrettsyndromepatients |